| Nesina (alogliptin) / Takeda |
NCT01686711: A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322 |
|
|
| Completed | 4 | 207 | Japan | AD-4833 15 mg, AD-4833 30 mg, Placebo | Takeda | Diabetes Mellitus | 12/13 | 12/13 | | |
NCT02426294: Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin |
|
|
| Unknown status | 4 | 154 | RoW | Pioglitazone, Actos, Glimepiride, Amaryl | Pusan National University Hospital | Type 2 Diabetes Mellitus | 12/15 | 05/16 | | |
TRACK, NCT02771093: An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 27 | Japan | Trelagliptin, Alogliptin | Takeda | Type 2 Diabetes Mellitus | 04/17 | 04/17 | | |
NCT03042325: Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus |
|
|
| Withdrawn | 4 | 0 | NA | Alogliptin, SYR-322, Nesina | Takeda | Diabetes Mellitus, Type 2 | 01/18 | 01/18 | | |
NCT03231709: Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 60 | Japan | Trelagliptin, Alogliptin | Takeda | Type 2 Diabetes Mellitus | 02/18 | 02/18 | | |
| Recruiting | 4 | 36 | Europe | Metformin / alogliptin Oral Product, Metformin / Pioglitazone Pill, triple therapy | University of Catanzaro | Diabetes Mellitus, Type 2 | 09/20 | 06/21 | | |
ChiCTR-IPR-17013314: The effects of Alogliptin on the intestinal flora of type 2 diabetes mellitus patients in China |
|
|
| Recruiting | 4 | 60 | | Alogliptin+Lifestyle intervention ;Lifestyle intervention | Peking University Shenzhen Hospital; Level of the institution：, Health and family planning commission of Shenzhen municipality | Type 2 Diabets | | | | |
ACADEMIC, NCT03794336: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive |
|
|
| Completed | 4 | 1293 | RoW | Alogliptin, Nesina, Acarbose, Glucobay, Metformin, Aspirin, Bayaspirin | Sanofi | Type 2 Diabetes Mellitus | 12/20 | 12/20 | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
ChiCTR2500103072: A single-center, single-arm efficacy study evaluating the effects of alogliptin on HbA1c levels and blood glucose control in patients with type 2 diabetes mellitus (T2DM) experiencing relapse after 12 weeks of treatment |
|
|
| Not yet recruiting | 4 | 60 | | Treated with codagliptin | Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology, Self-funded | Type 2 diabetes mellitus | | | | |
NCT07289750: The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD. |
|
|
| Not yet recruiting | 4 | 80 | NA | combination treatment, alone treatment | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | T2DM, MAFLD | 08/27 | 08/27 | | |
